Tandem糖尿病在第四季度盈利超过预期后上升

2026-02-20 06:30

Tandem Diabetes Care (TNDM) is up ~5% in after-hours trading Thursday after posting Q4 2025 financial results that beat on both lines.
The company also released 2026 revenue guidance of $1.065B-$1.085B. Consensus is $1.1B.
Q4 GAAP EPS of ($0.01) compares to the same figure in the year-ago period.
On a non-GAAP basis, sales increased 14% year over year in the US to ~$210.5M and internationally 15% to ~$290.4M.
Tandem ended 2025 with cash, cash equivalents, and short-term investments of ~$292.7M compared to ~$438.3M on Dec. 31, 2024.

More on Tandem Diabetes Care